Pfizer Inc. (NYSE:PFE) EVP Rady A. Johnson sold 27,323 shares of the firm’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $36.55, for a total value of $998,655.65. Following the completion of the sale, the executive vice president now owns 70,332 shares in the company, valued at $2,570,634.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Pfizer Inc. (PFE) opened at $36.78 on Friday. The stock has a market capitalization of $216,386.63, a PE ratio of 10.48, a P/E/G ratio of 2.05 and a beta of 0.91. Pfizer Inc. has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. The firm had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. Pfizer’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.47 earnings per share. analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were issued a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.70%. The ex-dividend date of this dividend was Thursday, February 1st. Pfizer’s payout ratio is presently 38.75%.
Pfizer declared that its board has initiated a share repurchase program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Large investors have recently added to or reduced their stakes in the stock. Investment Centers of America Inc. grew its stake in Pfizer by 2.3% during the 3rd quarter. Investment Centers of America Inc. now owns 195,611 shares of the biopharmaceutical company’s stock valued at $6,990,000 after acquiring an additional 4,472 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its stake in Pfizer by 437.9% during the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock valued at $27,607,000 after acquiring an additional 629,361 shares in the last quarter. Stanley Laman Group Ltd. grew its stake in Pfizer by 373.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after acquiring an additional 90,160 shares in the last quarter. Atlantic Trust LLC grew its stake in Pfizer by 19.8% during the 2nd quarter. Atlantic Trust LLC now owns 27,400 shares of the biopharmaceutical company’s stock valued at $748,000 after acquiring an additional 4,530 shares in the last quarter. Finally, ProVise Management Group LLC grew its stake in Pfizer by 5.9% during the 2nd quarter. ProVise Management Group LLC now owns 244,076 shares of the biopharmaceutical company’s stock valued at $8,198,000 after acquiring an additional 13,616 shares in the last quarter. 71.41% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on the company. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. SunTrust Banks reiterated a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Morgan Stanley raised their target price on Pfizer from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. UBS set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Societe Generale set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $39.40.
ILLEGAL ACTIVITY WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2018/03/17/insider-selling-pfizer-inc-pfe-evp-sells-998655-65-in-stock.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.